228 related articles for article (PubMed ID: 21327470)
1. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
[TBL] [Abstract][Full Text] [Related]
2. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
[TBL] [Abstract][Full Text] [Related]
3. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations of CCND1 and EMSY in breast cancers.
Kirkegaard T; Nielsen KV; Jensen LB; Campbell FM; Müller S; Tovey SM; Brown S; Cooke TG; Bartlett JM
Histopathology; 2008 May; 52(6):698-705. PubMed ID: 18393977
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
Holm K; Staaf J; Jönsson G; Vallon-Christersson J; Gunnarsson H; Arason A; Magnusson L; Barkardottir RB; Hegardt C; Ringnér M; Borg A
Breast Cancer Res Treat; 2012 Jun; 133(2):583-94. PubMed ID: 22002566
[TBL] [Abstract][Full Text] [Related]
6. EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.
Navazio AS; Rizzolo P; Silvestri V; Valentini V; Zelli V; Zanna I; Masala G; Bianchi S; Tommasi S; Palli D; Ottini L
Breast Cancer Res Treat; 2016 Nov; 160(1):181-186. PubMed ID: 27628328
[TBL] [Abstract][Full Text] [Related]
7. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome.
Rodriguez C; Hughes-Davies L; Vallès H; Orsetti B; Cuny M; Ursule L; Kouzarides T; Theillet C
Clin Cancer Res; 2004 Sep; 10(17):5785-91. PubMed ID: 15355907
[TBL] [Abstract][Full Text] [Related]
8. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D
Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351
[TBL] [Abstract][Full Text] [Related]
9. The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis.
Baykara O; Dalay N; Bakir B; Bulut P; Kaynak K; Buyru N
Int J Med Sci; 2017; 14(7):675-679. PubMed ID: 28824300
[No Abstract] [Full Text] [Related]
10. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.
Hughes-Davies L; Huntsman D; Ruas M; Fuks F; Bye J; Chin SF; Milner J; Brown LA; Hsu F; Gilks B; Nielsen T; Schulzer M; Chia S; Ragaz J; Cahn A; Linger L; Ozdag H; Cattaneo E; Jordanova ES; Schuuring E; Yu DS; Venkitaraman A; Ponder B; Doherty A; Aparicio S; Bentley D; Theillet C; Ponting CP; Caldas C; Kouzarides T
Cell; 2003 Nov; 115(5):523-35. PubMed ID: 14651845
[TBL] [Abstract][Full Text] [Related]
11. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas.
Madjd Z; Akbari ME; Zarnani AH; Khayamzadeh M; Kalantari E; Mojtabavi N
Asian Pac J Cancer Prev; 2014; 15(4):1783-9. PubMed ID: 24641409
[TBL] [Abstract][Full Text] [Related]
12. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
13. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
15. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
[TBL] [Abstract][Full Text] [Related]
17. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of EMSY gene amplification in human cancers.
Wilkerson PM; Dedes KJ; Wetterskog D; Mackay A; Lambros MB; Mansour M; Frankum J; Lord CJ; Natrajan R; Ashworth A; Reis-Filho JS
J Pathol; 2011 Sep; 225(1):29-42. PubMed ID: 21735447
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
[TBL] [Abstract][Full Text] [Related]
20. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
